News Headlines

  1. Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements With Cambrex And Thermo Fisher Scientific For Drug Substance And Drug Product Supply 6/25/2025

    Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the recent execution of agreements for the production of AD04 (0.33 mg ondansetron tablets), supporting both the completion of upcoming clinical trials and the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for the treatment of Alcohol Use Disorder (AUD) in the US.

  2. AGC Biologics Expands Cell Therapy Development Operations To Asia To Serve Growing Market Need 6/25/2025

    Today, we announced we will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical Center, marking the latest step in the global expansion of the company’s Global Cell and Gene Technologies Division. The improved geographical footprint allows AGC Biologics to better serve customers requiring autologous and allogeneic products across all markets, with cell therapy manufacturing now available in three continents (Milan, Italy – Longmont, Colorado, U.S. – Yokohama, Japan).  

  3. TAG1 And PharmaLogic Announce Strategic Partnership To Advance Decentralized Lead-212 Generator Development 6/24/2025

    TAG1 Inc., a premier supplier of clinical quantities of medical isotopes, today announced a strategic partnership with PharmaLogic, a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals.

  4. Starton Therapeutics And Bend Bioscience Enter Into Development Agreement For Oral Controlled Release Dosage Form Of STAR-LLD (Lenalidomide) 6/24/2025

    Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, today announced a collaboration agreement with Bend Bioscience (“Bend”), a leading innovation, science, and pharmaceutical services partner, whereby Bend will provide drug delivery R&D support and manufacturing capabilities for Starton’s lead candidate, STAR-LLD, a proprietary oral sustained release dosage form of lenalidomide.

  5. Axcelead And A2 Healthcare Announce Strategic Partnership To Accelerate Drug R&D 6/24/2025

     Axcelead, Inc. (Axcelead) and A2 Healthcare Corporation (A2 Healthcare) announced that they will enter a strategic partnership to promote pharmaceutical research and development in Japan.

  6. Nippon Shokubai Plans To Expand Its GMP-Compliant Nucleic Acid Drug API Manufacturing Capacity Tenfold 6/24/2025

    NIPPON SHOKUBAI CO., LTD. headquartered in Osaka, Japan, has announced a plan to expand its GMP (*1)-compliant manufacturing capacity for nucleic acid drug "active pharmaceutical ingredients" (APIs) tenfold in response to rapidly growing global demand in the nucleic acid drug market.

  7. Xcell Biosciences Announces Joint Research Collaboration With Thermo Fisher Scientific To Advance The Next Generation Of Cell Therapies 6/24/2025

    Xcell Biosciences (Xcellbio), a San Francisco-based instrumentation company focused on cell and gene therapy applications, today announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, to advance research in regulatory T cells (Tregs) and tumor-infiltrating lymphocytes (TILs).

  8. Fujirebio Acquires Plasma Services Group And Strengthens Its Position As Provider Of Critical And High Quality Biological Raw Materials To The IVD And Life Science Industries 6/23/2025

    H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter “Plasma Services Group”). The transaction value has not been disclosed.

  9. The Flamma Group Expands Globally Reinforcing Its Commitment To Growth 6/23/2025

    The Flamma Group (“Flamma”) is a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry.

  10. PharmaLogic Completes Acquisition Of Majority Stake In Agilera Pharma AS 6/23/2025

    PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the completion of its previously announced acquisition of a majority stake in Agilera Pharma AS ("Agilera") from the Institute for Energy Technology (IFE) in Norway, marking a significant step forward in the company's strategy to create the first fully-integrated, global CDMO platform specializing in radiopharmaceutical therapeutics.